This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Gasparini, G. Search for Related Content PubMed PubMed Citation Articles by Gasparini, G.

Prognostic Value of Vascular Endothelial Growth Factor in Breast Cancer

Division of Medical Oncology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy

Correspondence: Giampietro Gasparini, M.D., Director, Department of Oncology, and Head, Division of Medical Oncology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Via Melacrino 89100, Reggio, Calabria, Italy. Telephone: 011390965-397331; Fax: 011390965-397334; e-mail: oncologiarc{at}diel.it

Angiogenesis, the process leading to the formation of new blood vessels from a preexisting vascular network, is necessary for tumor growth, invasion, and metastasis. Data from experimental and clinical studies indicate that breast carcinoma is an angiogenesis-dependent tumor.

Most retrospective studies evaluating the prognostic value of determination of intratumoral microvessel density (IMD) at the vascular "hot spot" (a surrogate marker of angiogenesis) found that IMD is a significant and independent prognostic indicator in patients with both node-negative and node-positive breast cancers. More recently, the expression of certain endothelial growth factors has been tested. Among these, vascular endothelial growth factor (VEGF), the most potent endothelial cell mitogen and also a regulator of vascular permeability, is emerging as a powerful new prognostic tool. Eight of the nine published retrospective studies reported that VEGF is significantly associated with relapse-free survival, overall survival, or both. Patients with early stage breast cancer who have tumors with elevated levels of VEGF have a higher likelihood of recurrence or death than patients with low-angiogenic tumors, even if treated with conventional adjuvant therapy.

High levels of VEGF can differentiate the subgroups of patients with breast cancer with poor prognosis who benefit minimally from conventional adjuvant therapy but who may benefit from validated anti-VEGF treatments.

Key Words. Angiogenesis • Breast cancer • Prognosis • Vascular endothelial growth factor

This article has been cited by other articles:

				G. E. Lavalle, A. C. Bertagnolli, W. L. F. Tavares, and G. D. Cassali Cox-2 Expression in Canine Mammary Carcinomas: Correlation with Angiogenesis and Overall Survival Veterinary Pathology, November 1, 2009; 46(6): 1275 - 1280. [Abstract] [Full Text] [PDF]

				I. H. Ozbudak, G. Ozbilim, I. Kucukosmanoglu, L. Dertsiz, and A. Demircan Vascular Endothelial Growth Factor Expression and Neovascularization in Non--Small Cell Lung Carcinoma International Journal of Surgical Pathology, October 1, 2009; 17(5): 390 - 395. [Abstract] [PDF]

				J. W. Pollard Macrophages define the invasive microenvironment in breast cancer J. Leukoc. Biol., September 1, 2008; 84(3): 623 - 630. [Abstract] [Full Text] [PDF]

				S. K. Chang, I. Rizvi, N. Solban, and T. Hasan In vivo Optical Molecular Imaging of Vascular Endothelial Growth Factor for Monitoring Cancer Treatment Clin. Cancer Res., July 1, 2008; 14(13): 4146 - 4153. [Abstract] [Full Text] [PDF]

				J. Du, F.-H. Li, H. Fang, J.-G. Xia, and C.-X. Zhu Correlation of Real-time Gray Scale Contrast-Enhanced Ultrasonography With Microvessel Density and Vascular Endothelial Growth Factor Expression for Assessment of Angiogenesis in Breast Lesions J. Ultrasound Med., June 1, 2008; 27(6): 821 - 831. [Abstract] [Full Text] [PDF]

				J. Hattangadi, C. Park, J. Rembert, C. Klifa, J. Hwang, J. Gibbs, and N. Hylton Breast Stromal Enhancement on MRI Is Associated with Response to Neoadjuvant Chemotherapy Am. J. Roentgenol., June 1, 2008; 190(6): 1630 - 1636. [Abstract] [Full Text] [PDF]

				H. J. Burstein, A. D. Elias, H. S. Rugo, M. A. Cobleigh, A. C. Wolff, P. D. Eisenberg, M. Lehman, B. J. Adams, C. L. Bello, S. E. DePrimo, et al. Phase II Study of Sunitinib Malate, an Oral Multitargeted Tyrosine Kinase Inhibitor, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane J. Clin. Oncol., April 10, 2008; 26(11): 1810 - 1816. [Abstract] [Full Text] [PDF]

				D. R. Emlet, K. A. Brown, D. L. Kociban, A. A. Pollice, C. A. Smith, B. B. L. Ong, and S. E. Shackney Response to trastuzumab, erlotinib, and bevacizumab, alone and in combination, is correlated with the level of human epidermal growth factor receptor-2 expression in human breast cancer cell lines Mol. Cancer Ther., October 1, 2007; 6(10): 2664 - 2674. [Abstract] [Full Text] [PDF]

				E. Zygalaki, E. G. Tsaroucha, L. Kaklamanis, and E. S. Lianidou Quantitative Real-Time Reverse Transcription PCR Study of the Expression of Vascular Endothelial Growth Factor (VEGF) Splice Variants and VEGF Receptors (VEGFR-1 and VEGFR-2) in Non Small Cell Lung Cancer Clin. Chem., August 1, 2007; 53(8): 1433 - 1439. [Abstract] [Full Text] [PDF]

				Z. Ma, S. L. Gibson, M. A. Byrne, J. Zhang, M. F. White, and L. M. Shaw Suppression of Insulin Receptor Substrate 1 (IRS-1) Promotes Mammary Tumor Metastasis Mol. Cell. Biol., December 15, 2006; 26(24): 9338 - 9351. [Abstract] [Full Text] [PDF]

				G. S. O. Missotten, I. C. Notting, R. O. Schlingemann, H. J. Zijlmans, C. Lau, P. H. C. Eilers, J. E. E. Keunen, and M. J. Jager Vascular Endothelial Growth Factor A in Eyes With Uveal Melanoma Arch Ophthalmol, October 1, 2006; 124(10): 1428 - 1434. [Abstract] [Full Text] [PDF]

				L. Manenti, E. Riccardi, S. Marchini, E. Naumova, I. Floriani, A. Garofalo, R. Dossi, E. Marrazzo, D. Ribatti, E. Scanziani, et al. Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy Mol. Cancer Ther., May 1, 2005; 4(5): 715 - 725. [Abstract] [Full Text] [PDF]

				H. S. Rugo Bevacizumab in the Treatment of Breast Cancer: Rationale and Current Data Oncologist, June 1, 2004; 9(suppl_1): 43 - 49. [Abstract] [Full Text] [PDF]

				F. Millanta, G. Lazzeri, I. Vannozzi, P. Viacava, and A. Poli Correlation of Vascular Endothelial Growth Factor Expression to Overall Survival in Feline Invasive Mammary Carcinomas Veterinary Pathology, November 1, 2002; 39(6): 690 - 696. [Abstract] [Full Text] [PDF]

				M. Stimpfl, D. Tong, B. Fasching, E. Schuster, A. Obermair, S. Leodolter, and R. Zeillinger Vascular Endothelial Growth Factor Splice Variants and Their Prognostic Value in Breast and Ovarian Cancer Clin. Cancer Res., July 1, 2002; 8(7): 2253 - 2259. [Abstract] [Full Text] [PDF]

				A. Bottini, A. Berruti, A. Bersiga, M. P. Brizzi, G. Allevi, G. Bolsi, S. Aguggini, A. Brunelli, E. Betri, D. Generali, et al. Changes in Microvessel Density As Assessed by CD34 Antibodies after Primary Chemotherapy in Human Breast Cancer Clin. Cancer Res., June 1, 2002; 8(6): 1816 - 1821. [Abstract] [Full Text] [PDF]

				M. Trikha, Z. Zhou, J. Timar, E. Raso, M. Kennel, E. Emmell, and M. T. Nakada Multiple Roles for Platelet GPIIb/IIIa and {alpha}v{beta}3 Integrins in Tumor Growth, Angiogenesis, and Metastasis Cancer Res., May 1, 2002; 62(10): 2824 - 2833. [Abstract] [Full Text] [PDF]

				S. J. Freemantle and E. Dmitrovsky Clinical Link Between p53and Angiogenesis in Lung Cancer J. Clin. Oncol., February 15, 2002; 20(4): 883 - 884. [Full Text] [PDF]

				C. C. Solorzano, Y. D. Jung, C. D. Bucana, D. J. McConkey, G. E. Gallick, G. McMahon, and L. M. Ellis In Vivo Intracellular Signaling as a Marker of Antiangiogenic Activity Cancer Res., October 1, 2001; 61(19): 7048 - 7051. [Abstract] [Full Text] [PDF]